Biomarin Pharmaceutical Inc BMRN
Deals with insiders in the proxy filed Apr 21, 2026
Proxy, Item 404Deals between BMRN and its directors, executives, owners of more than 5% or their families: a relative on the payroll, a plane the company charters from its CEO, a director's company that buys from it. SEC rules (Item 404) make the company list every such deal over $120,000 in its proxy statement.
New this year
Compared with Apr 8, 2025
Paragraphs about a deal, a person or a relative with nothing like them in the proxy filed Apr 8, 2025.
Review, Approval, and Ratification of Transactions with Related Parties“During 2025, the Compensation Committee was composed of Ms. Anderson (Chair), Dr. Dere, Dr. Ho, Mr. Hombach and Mr. Walbert as well as Dr. David E.I. Pyott, a former director whose term as a director concluded at the 2025 Annual Meeting. No member of our Compensation Committee has ever been an executive officer or employee of us or any of our subsidiaries. None of our executive officers currently serves, or has served during the last completed fiscal year, on the Compensation Committee or board of directors of any other entity that has one or more executive officers serving as a member of our Board or Compensation Committee. During 2025, no members of our Compensation Committee had any relationships requiring disclosure by us under the SEC’s rules requiring disclosure of certain relationships and related party transactions.”
Read it in the proxyopen_in_new
The whole section
As filed
6 paragraphs quoted as filed
Transactions with Related Persons, Promoters and Certain Control Persons“Since January 1, 2025, there has not been nor is there currently proposed any transaction or series of similar transactions to which we or one or more of our subsidiaries were or are to be a party in which the amount involved exceeds $120,000 and in which any director, executive officer, holder of more than 5% of our common stock, or any member of the immediate family of any of the foregoing persons, had or will have a direct or indirect material interest other than compensation agreements and other arrangements, which are described elsewhere in this Proxy Statement.”
Read it in the proxyopen_in_new
Review, Approval, and Ratification of Transactions with Related Parties“Our Audit Committee has primary responsibility for reviewing and approving in advance or ratifying all related party transactions. In conformance with SEC regulations, we define related persons to include our executive officers, our directors and nominees to become a director of our Company, any person who is known to us to be the beneficial owner of more than 5% of any class of our voting securities, any immediate family member of any of the foregoing persons, and any firm, corporation or other entity in which any of the foregoing persons is employed, is a general partner or in which such person has a 5% or greater beneficial ownership interest.”
Read it in the proxyopen_in_new
Review, Approval, and Ratification of Transactions with Related Parties“We have several processes that we use to ensure that we identify and review all related party transactions. First, each executive officer is required to notify either our Chief Legal Officer or CFO of any potential transaction that could create a conflict of interest, and the Chief Legal Officer or CFO is required to notify the Audit Committee of the potential conflict. The directors, CEO, CFO and Chief Legal Officer are required to notify the Audit Committee of any potential transaction that could create a conflict of interest. Second, each year, we require our directors and executive officers to complete director and officer questionnaires identifying any transactions with us in which the executive officer or director or their family members have an interest.”
Read it in the proxyopen_in_new
Review, Approval, and Ratification of Transactions with Related Parties“The Audit Committee reviews related party transactions due to the potential for such transactions to create a conflict of interest. A conflict of interest occurs when an individual’s private interest interferes, or appears to interfere, with our interests. Our Board or its committees only approve a related party transaction if it is determined that a transaction is in the best interest of the stockholders or is at least not inconsistent with those interests. This includes situations where the Company may obtain products or services of a nature, quantity or quality, or on other terms, that are not readily available from alternative sources or when the transaction is on terms comparable to those that could be obtained in arm’s length dealings with an unrelated third party.”
Read it in the proxyopen_in_new
Review, Approval, and Ratification of Transactions with Related Parties“These policies and procedures are included in our Corporate Governance Principles, which are available in the “Governance” subsection of the “Investors” section of our website at www.biomarin.com. Information on our website is NOT incorporated by reference into this Proxy Statement.”
Read it in the proxyopen_in_new
Review, Approval, and Ratification of Transactions with Related Parties“During 2025, the Compensation Committee was composed of Ms. Anderson (Chair), Dr. Dere, Dr. Ho, Mr. Hombach and Mr. Walbert as well as Dr. David E.I. Pyott, a former director whose term as a director concluded at the 2025 Annual Meeting. No member of our Compensation Committee has ever been an executive officer or employee of us or any of our subsidiaries. None of our executive officers currently serves, or has served during the last completed fiscal year, on the Compensation Committee or board of directors of any other entity that has one or more executive officers serving as a member of our Board or Compensation Committee. During 2025, no members of our Compensation Committee had any relationships requiring disclosure by us under the SEC’s rules requiring disclosure of certain relationships and related party transactions.”
Read it in the proxyopen_in_new
Paragraphs are compared by their words, not read by AI: one counts as new when no paragraph last year shares half of its words, or when it names a person or company last year's section did not. A deal reported again with a new amount is not new. Always check the filing. Open the proxy ↗ · Last year's proxy ↗
Sources
The related-party section (Item 404) of the latest annual proxy statement (DEF 14A), against last year's, compared by their words.
Also
CEO pay: the same proxy's pay versus performance table.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BMRN/export.csv") into a cell.